Beijing Luzhu Biotechnology Co., Ltd. (02480.HK)

Beijing Luzhu Biotechnology Co., Ltd. engages in the development, production, and sale of active pharmaceutical ingredients. The company is headquartered in Beijing, Beijing and currently employs 197 full-time employees. The company went IPO on 2023-05-08. The firm is also engaged in the development of innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The firm's products include clinical-stage product candidates and pre-clinical-stage product candidates. The core product LZ901 is mainly used to prevent shingles caused by the varicella-zoster virus in adults aged 50 years and above. The firm mainly conducts its businesses in the domestic market.